0001104659-23-040289.txt : 20230331
0001104659-23-040289.hdr.sgml : 20230331
20230331170659
ACCESSION NUMBER: 0001104659-23-040289
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230330
FILED AS OF DATE: 20230331
DATE AS OF CHANGE: 20230331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Golembiewski Michael Joseph
CENTRAL INDEX KEY: 0001639479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 23789030
MAIL ADDRESS:
STREET 1: 7 TURTLE CT
CITY: FLEMINGTON
STATE: NJ
ZIP: 08822
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
tm2311208-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-03-30
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001639479
Golembiewski Michael Joseph
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 2ND FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Financial Officer
0
Stock Option (right to buy)
0.69
2023-03-30
4
A
0
677701
0.00
A
2033-03-30
Common Stock
677701
677701
D
Stock Option (right to buy)
0.69
2023-03-30
4
A
0
88030
0.00
A
2023-03-30
2033-03-30
Common Stock
88030
88030
D
1/4th of the shares subject to the option shall vest on March 30, 2024, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through such vesting date.
The Reporting Person voluntarily elected to be paid 35% of his 2022 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer.
/s/ Michael Golembiewski
2023-03-31